AbbVie Replaced the Humira Cliff Without Solving It: Two Drugs Now Supply 98% of Growth, and Skyrizi's 2033 Expiry Is the Date Nobody Is Pricing

The market's worst fear about AbbVie was a collapse. That fear has been retired. Trailing-twelve-month revenue of $66.014 billion is 21.5% above the $54.318 billion AbbVie reported in 2023, the first full year of Humira biosimilar competition, and trailing gross margin has climbed to 76.2% from 62.4% in 2023. The recovery was real. It was also not diversified: it was built almost entirely on two molecules, which is why the company emerging from the 2023 cliff looks less like a broad pharmaceutical and more like a royalty on two assets with a shared expiry date.

The concentration is best seen in one subtraction. In the third quarter of 2025, Skyrizi earned $4.708 billion and Rinvoq $2.184 billion, against total company revenue of $15.776 billion. A year later they earned $5.776 billion and $2.706 billion, against $17.404 billion. The pair added $1.590 billion while the company added $1.628 billion, so roughly 98% of the quarter's growth came from two molecules and the other forty-odd product lines netted to about $37 million.

The earnings inflection is widely read as an operating achievement. It is not. Trailing gross profit of $50.337 billion on $66.014 billion of revenue is a 76.2% gross margin, against 70.2% for full-year 2025 and 62.4% for 2023. No cost program explains it: trailing research and development is $9.962 billion, or 15.1% of revenue, and AbbVie's own 10-K reports research intensity of 15% in 2025 against 14% in 2023. Selling, general and administrative expense actually rose to 23.5% of revenue in the third quarter from 22.6% a year earlier, while research and development held at 14.7%. AbbVie delivered the margin gain through mix rather than cost control, and the same mix is what raises the stakes on 2033.

The instinct after any patent-cliff story is to hunt for the government price cut next. For AbbVie, the selection list says look again. On Jan. 27, 2026, the Centers for Medicare and Medicaid Services named 15 drugs for the third round of Medicare drug price negotiation, with negotiated prices effective Jan. 1, 2028. AbbVie had two entries, Botox and Xeljanz. Neither Skyrizi nor Rinvoq was selected, and the selection list makes the Medicare price cut a second-order risk for the two assets that determine the company's value.

That does not remove the policy risk, it relocates it. CMS's own ranking of the 50 drugs most exposed to negotiation for 2028 puts Botox ninth on $1.14 billion of Medicare spending and Xeljanz 13th on $1.01 billion, both small against the $34 billion annualized run rate of Skyrizi and Rinvoq. The fourth selection round, announced in January 2027 for prices effective Jan. 1, 2029, is the next checkpoint, and it is live: Skyrizi generated $4.767 billion of US revenue in the June quarter alone, and Rinvoq is an oral therapy dispensed largely through the Medicare benefit.

AbbVie's 2025 Form 10-K states that the United States composition-of-matter patents covering risankizumab and upadacitinib are expected to expire in 2033. On Sept. 11, 2025, the company disclosed a settlement with every generic manufacturer that had filed an abbreviated new drug application for upadacitinib, and said it does not expect US generic entry before April 2037, assuming paediatric exclusivity is granted. So one of the two engines is legally protected for eleven years and the other for seven. Skyrizi puts a $23 billion franchise on a seven-year clock, and Skyrizi is the one with no settlement deferral.

The size of that exposure is easy to understate because it is spread across two lines of the income statement. Skyrizi's US net revenues were $15.2 billion in 2025 out of $17.6 billion globally, and Rinvoq's US net revenues were $5.94 billion out of $8.30 billion. Together, US sales of the two molecules were $21.1 billion, or 34.6% of AbbVie's $61.2 billion of revenue, and that revenue is what a 2033 US expiry puts at risk.

Humira did not fall off a patent cliff; it was taken. Amgen launched Amjevita, the first US adalimumab biosimilar, in January 2023. Adalimumab biosimilars held only about 2% of the US market one year after US competition began, then reached roughly 22% by October 2024, and Humira's global revenue fell 37.2% in the third quarter of 2024 alone. That industry is now pointed at Skyrizi. No risankizumab biosimilar is approved in the United States, but the manufacturing base that would supply one is already built and already profitable.

On the generic side of the same franchise, the challengers are named. AbbVie's November 2023 complaints went after Hetero, Aurobindo, Sandoz, Intas, Accord and Sun for filing ANDAs on upadacitinib. The September 2025 settlements resolved all of them, and the price of that resolution is a licence that pushes US generic entry to April 2037. The upstream suppliers of AbbVie's next patent cliff are therefore both known and, for the moment, contractually held at bay.

AbbVie's cash arrives through a narrow pipe. Three US wholesalers accounted for 82% of net accounts receivable at June 30, 2026, down from 84% at the end of 2025, and every Skyrizi and Rinvoq prescription passes through that channel before it reaches a patient. The listed operators of the specialty channel, Cencora, McKesson and CVS Health, are paid on branded script volume and on the negotiated prices the government sets, not on the manufacturer's patent calendar. It is also where the economics look very different from the manufacturer's.

The mispricing runs opposite to the usual pharmaceutical argument. AbbVie trades at 24.2 times trailing enterprise value to EBITDA with a 3.5% free cash flow yield. That is below Eli Lilly at 30.8 times and Merck at 31.9 times, the two large caps the market treats as durable, and far above Bristol-Myers Squibb at 10.6 times with a 7.3% yield, the multiple the market applies to a pharma it believes is living through a patent cliff. AbbVie has a patent cliff too. It is simply seven years out and it sits on 48.7% of revenue. AbbVie prices a seven-year cliff at a premium to the market's cliff-pharma multiple.

What the market has actually paid for is earnings, not a re-rating. AbbVie's enterprise value to trailing EBITDA actually fell from 26.6 times at the end of 2025 to 24.2 times, because trailing EBITDA grew 37% from $17.6 billion to $24.2 billion, while the free cash flow yield compressed from 4.4% to 3.5%. The shares did the work: market value rose from $405.3 billion at the end of 2025 to $463.5 billion at the Sept. 30 quarter-end and roughly $521 billion after the Oct. 30 print. What nobody has paid for is the denominator that makes the multiple look reasonable, because that denominator is built on a patent with seven years left.

Over the next three quarters the calendar is crowded and specific. The fourth-quarter results, due in early February 2027, carry the first formal 2027 guidance, and management has already told investors to expect another year of top-tier growth. On the product side, the FDA approved a subcutaneous induction regimen for Skyrizi in Crohn's disease on Oct. 23, 2026, on the back of phase 3 AFFIRM data presented Oct. 13, and AbbVie submitted an application to the European Medicines Agency for subcutaneous Skyrizi in August. Etentamig is expected to be approved in the United States in 2027, Epkinly's frontline submission in diffuse large B-cell lymphoma is planned for early 2027, zumilokibart, acquired with Apogee Therapeutics, is due to start phase 3 in atopic dermatitis, and emraclidine is scheduled to enter phase 2 by the end of 2026.

AbbVie has done something genuinely difficult. It replaced its largest biologic franchise with two newer ones without an air pocket: trailing revenue is 21.5% above the 2023 post-cliff trough, trailing gross margin is 13.8 points higher, and free cash flow through June 2026 of $18.21 billion comfortably covered $11.98 billion of dividends and $1.51 billion of buybacks. On any one-year view this is a well-run company compounding, and the third quarter was the proof of it.

On a seven-year view it is a two-asset royalty with an 85.1% gross margin, 48.7% of revenue in two molecules, $21.1 billion of 2025 US revenue exposed to a 2033 patent expiry, and an immunology pipeline that does not deliver its next major readouts until late 2029. The honest reading of the Oct. 30 print is that AbbVie has bought itself seven clean years and has not started paying for them. AbbVie bought seven years of clean compounding without starting to pay for them, and the share price, up roughly 12% on the print, now assumes the loan is never called.